Back to top
more

ABIOMED, Inc. (ABMD)

(Delayed Data from NSDQ)

$271.75 USD

271.75
1,074,902

+6.98 (2.64%)

Updated May 3, 2019 04:00 PM ET

After-Market: $271.72 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Headquartered in Danvers, MA and founded in 1981, ABIOMED Inc. (ABMD) is engaged in developing, manufacturing and marketing of medical products, designed to assist or replace the pumping function of the failing heart. Abiomed’s main product line - Impella - comprises Impella 2.5, Impella 5.0, Impella LD, Impella CP and Impella RP.

Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?

by Zacks Equity Research

Sector ETF report for XHE

Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XHE

Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?

by Zacks Equity Research

Sector ETF report for XHE

3 Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio

by Zacks Equity Research

Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.

Why Is Abiomed (ABMD) Up 1.2% Since Last Earnings Report?

by Zacks Equity Research

Abiomed (ABMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Hold on to Abiomed (ABMD) Stock Now

by Zacks Equity Research

Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.

Is Molina Healthcare (MOH) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Molina (MOH) and Abiomed (ABMD) have performed compared to their sector so far this year.

Company News for Nov 2, 2022

by Zacks Equity Research

Companies in The News Are: ABMD,ARCB,MPC,TAP

ABIOMED, Inc. (ABMD) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Abiomed (ABMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Sejuti Banerjea headshot

3 Stocks That Popped Yesterday

by Sejuti Banerjea

We're in the middle of earnings season, so it would be natural to assume that earnings reports are the biggest drivers of stocks during the season. But that isn't the case with a bunch that soared yesterday.

Pre-Markets in Green to Start a Fresh Month

by Zacks Equity Research

Pre-Markets in Green to Start a Fresh Month

Abiomed (ABMD) Q2 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Abiomed's (ABMD) strength in Impella product revenues drives its Q2 top line.

Mark Vickery headshot

Pre-Markets Up Ahead of New Fed Hike, Q3 Beats

by Mark Vickery

Big Pharma giants Pfizer (PFE) and Lilly (LLY) posted beats on both top and bottom lines this morning, while J&J (JNJ) is buying Abiomed (ABMD).

Abiomed (ABMD) Beats Q2 Earnings Estimates

by Zacks Equity Research

Abiomed (ABMD) delivered earnings and revenue surprises of 23.81% and 2.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Debanjana Dey headshot

MedTech Stocks Due to Report Earnings on Nov 1: MCK, CTLT & More

by Debanjana Dey

MedTech companies' Q3 results are likely to reflect strength in customer demand. Let's see how MCK, CTLT, ECL, ABMD, HSIC and IDXX are placed ahead of their earnings releases.

Is Abiomed (ABMD) a Solid Growth Stock? 3 Reasons to Think "Yes"

by Zacks Equity Research

Abiomed (ABMD) possesses solid growth attributes, which could help it handily outperform the market.

The Zacks Analyst Blog Highlights Nevro, Masimo, Abiomed and Glaukos

by Zacks Equity Research

Nevro, Masimo, Abiomed and Glaukos are part of the Zacks top Analyst Blog.

Indrajit Bandyopadhyay headshot

4 MedTech Stocks Set to Outpace Q3 Earnings Estimates

by Indrajit Bandyopadhyay

Let us take a look at some MedTech stocks, NVRO, MASI, ABMD and GKOS, which are poised to beat on third-quarter earnings.

Earnings Preview: Inari Medical, Inc. (NARI) Q3 Earnings Expected to Decline

by Zacks Equity Research

Inari Medical, Inc. (NARI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied Volatility Surging for Abiomed (ABMD) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Abiomed (ABMD) stock based on the movements in the options market lately.

McKesson (MCK) to Report Q2 Earnings: Is a Beat in the Cards?

by Zacks Equity Research

McKesson's (MCK) fiscal second-quarter results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.

Abiomed (ABMD) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven Q2 sales.

Abiomed (ABMD) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Abiomed (ABMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Molina Healthcare (MOH) to Post Q3 Earnings: What to Expect

by Zacks Equity Research

Molina Healthcare's (MOH) Q3 results are expected to reflect better premiums and membership growth in its Medicaid and Medicare businesses, partly offset by steep general and administrative costs.

Abiomed's (ABMD) Latest Impella Offering Approved by the FDA

by Zacks Equity Research

Abiomed's (ABMD) latest regulatory clearance for the Impella Low Profile Sheath is expected to improve patient outcomes.